ÎÄÕÂ
  • ÎÄÕÂ
搜索
Ê×Ò³ >> ²úÆ·×ÊѶ >>²úÆ·×ÊѶ >> NovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¿¹ÑÀ¾ú°ßºÍÑÀö¸Ñ×µÄÁÙ´²Ñо¿
详细内容

NovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¿¹ÑÀ¾ú°ßºÍÑÀö¸Ñ×µÄÁÙ´²Ñо¿

NovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¿¹ÑÀ¾ú°ßºÍÑÀö¸Ñ×µÄÁÙ´²Ñо¿

 

̨±£¾ü¶ÅÃñȨ½­ºº»ÆÞ±¹ùò«

(Î人´óѧ¿ÚǻҽѧԺУ·À¿Æºþ±±Î人430079)

 

[ÕªÒª]Ä¿µÄ£»ÆÀ¼ÛNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¿¹ÑÀ¾ú°ßºÍÑÀö¸Ñ×µÄÁÙ´²¹¦Ð§¡£·½·¨×ñÕÕËæ»ú¡¢Ë«ÓС¢¶ÔÕÕµÄÊÔÑéÔ­Ôò£¬°´ÄÉÈëºÍÅųý±ê×¼½«100ÃûÄêÁäÔÚ2o¡«48ËêµÄÊÜÊÔÕßËæ»ú·Ö³ÉÊÔÑé×é(ʹÓÃNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à)ºÍ¿Õ°×¶ÔÕÕ×é(ʹÓÃͬһ¹«Ë¾Éú²úµÄÆÕͨÑÀ¸à)£¬²ÉÓÃÎ÷°ßÖ¸ÊýºÍÑÀö¸³öѪָÊýÆÀ¼ÛÊÜÊÔÕßµÄÑÀö¸½¡¿µ

×´¿ö¡£½á¹û£ºÊÔÑé×é¾ú°ßÖ¸ÊýºÍÑÀö¸³öѪָÊýÓëÊÔÑéǰÏà±ÈÔÚͳ¼ÆÑ§ÉÏÓÐÏÔÖøÐÔ²îÒ죬ÊÔÑé6ÖܺóÑÀö¸³öѪָÊýºÍ¾ú°ßÖ¸Êý·Ö±ð½µµÍÁË58.8%ºÍ16.4ïöø¶ÔÕÕ×é¾ú°ßÖ¸ÊýºÍÑÀö¸³öѪָÊýÔÚͳ¼ÆÑ§ÉÏÎÞÏÔÖøÐÔ²îÒì(P¡µo.o5)¡£½áÂÛ±¾Ñо¿ÌáʾNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÄÜͨ¹ý¼õÉÙ¸úÉϾú°ßºÍ¼õÇáÑÀö¸³öѪ¶øÏÔÖø¸ÄÉÆÑÀö¸½¡¿µ×´¿ö¡£

¹Ø¼ü´Ê1ÉúÎï»îÐÔ²£Á§Àë×Ó¿¹¾ú°ß¿¹ÑÀö¸Ñ×ÑÀ¸à

[ÖÐͼ·ÖÀàºÅ]R780 1[ÎÄÏ×±êʶÂë]A[ÎÄÕ±àºÅ¡¿1671Ò»-7651(2005)06-0661--03

 

clinical study of Dentifrice contai ning NovaMin B ioacti vc Glass pa rticle on Anti-plaquelA nti-Gingivi tis. TA/

Bat?-j_DLF.  ¡¤ Mrn-qualr. Jr. 410 Ahn, rial.. *hool afjlolnaraAngy, tF  ¡¤ uAan taHir  ¡¤ ersjjv, ITh)}ai? 4. 1079

[Abstract]objectives The anti-plaque / anti-gingivitis pffiracy was evaluated clinically nrl a dpntifrice containing No2

vaMin Bi oactive Glass ( test) compared with dentifrice wi\hmJt Bi oartive class ( contr ol) over 6-week peri od. Methods

The studv design was a randomized, dnuhlp-6linoe4, ( ¡¤ (mtr oiled clinical trial. 1 o0 subjectswith age ranging fr om 20 Io 48

were randomly divided int o t wo gr oup s. thr test gr oup and \he contr ol gr oup. The Planue I ndex ( PL I ) and Cingiva1Ble € 82

ing Index (CB I ) were deter mined at the baseline and 6 weeks later. Results The Gingival Blpeding l nd€x (GB I) and

plaque Index ( pL lj were significantly reduced in the test gr ottp ( n-47) by 58. 8% and 16. 4%, res pectrvely, while

there was no difference of the C B I and pL I for the rontr ol gr o11p (.-48). Conclusion This study demonstrated that the

dentifrice containing Bi oactive Glass significantly I nip roved oral hralth asmeasurpd hy a rrduction in gingival bltaeding and

a reduct I on in supra-gingi va] p laque comparpd wi\h a free dentifrice over 6-week period.

[ Keyw ord¡ì] Bioactive Class Anti-gingivitis Anti-plaque Dentifrice

 

Nova MinÑÀ¸àÊÇÒ»ÖÖºÏÉúÎï»îÐÔ²£Á§Àë×ÓµÄÑÀ¸à£¬¸Ã²ÄÁÏÓɶàÖÖÎÞ»úÀë×Ó×é³É£¬°üÀ¨¹è¸Æ¡¢ÄƺÍÁ׵ȣ¬Ëü¾ßÓÐÒÖÖÆ¿ÚÇ»ÖÂȣϸ¾úºÍÑÀÖÜÏà¹ØÏ¸¾ú¼°¿¹ÑÀ±¾ÖʹýÃôµÄ×÷ÓÃl'"41¡£±¾Ñо¿µÄÄ¿µÄÊÇͨ¹ýΪÆÚ6ÖܵÄÁÙ´²ÊÔÑ飬ÆÀ¼ÛNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¶Ô¿ØÖÆÑÀ¾ú°ßºÍ¼õÇáÑÀö¸³öѪµÄÁÙ´²¹¦Ð§£¬Ñ°ÕÒÒ»ÖÖά»¤ÑÀö¸½¡¿µÇÒ°²È«ÓÐЧµÄÄÚÎÒ±£½¡ÓÃÆ·¡£

 

²ÄÁÏÓë·½·¨

1.1²¡ÀýÑ¡ÔñÔÚÁÙ´²ÊÔÑ鿪ʼǰ£¬ÏòÔ¸Õß¾ùÇ©ÊðÖªÇéͬÒâÊé²¢Ìṩҽѧ²¡Ê·¡£Î人´óѧµÀµÂÂ×ÀíίԱ»áÉóºË²¢Í¬ÒâÁ˱¾ÊÔÑé²Ý°¸¡£°´ÄÉÈëºÍÅųý±ê×¼¶Ô×ÔÔ¸Õß½øÐÐɸѡÒÔÈ·¶¨Ñù±¾ÈËȺ¡£ÄÉÈë±ê×¼ÄêÁäÔÚ18ËêÒÔÉÏÉíÌ彡¿µÓÐÈÕ³£Ë¢ÑÀϰ¹ßÖÁÉÙ2o°åÑÀµÄ¼ÕºóÃæ¿ÉÒԼǼÐÔ±ð²»ÏÞ¡£Åųý±ê×¼£ºÓÐϵͳÐÔ¼²²¡Ðпª·ÅÐÔÈ£¡£ÑÀËèÑס£ÑÀÖÜÑ×»¼Õß¹ÚÇźÍÕý»û»¼ÕßÈÑÉïÆÚºÍ²¸Èé}W¶ÔÑÀ¸à¹ýÃô¼°ÆäËû¿ÚÇ»ÎÀÉú²úÆ·¹ýÃôÕß³¤ÆÚʹ´¨¿¹ÉúËØÖÎÁÆÕß¡£

1.2ÊÔÑé·Ö×éÊÔÑé×ñÕÕËæ»ú¡¢Ë«°Ù¡¢¶ÔÕÕÔ­Ôò½øÐС£½«·ûºÏÌõ¼þµÄ100ÃûÊÜÊÔÐа´¼ÆËã»úÉú³ÉµÄËæ»úÊý×Ö½øÐзÖ×飬ÊÔÑé×é50ÃûʹÓÃNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à£¬¶ÔÕÕÈ«ft 50ÃûʹÓÃͬһ¹«Ë¾Éú²úµÄ²»º¬NovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¡£

1.3ÊÔÑé·½·¨ÊÜÊÔÕßʹÓÃÉÏÊöÑÀ¸àÔçÍí¸÷Ë¢ÑÀ1´Î£¬ÑÀ¸à±ØÐë²¼ÂúÕû¸öˢ룬ÿ´Îlm in¡£ÊÔÑé°üÀ¨3´Î¿ÚÇ»¼ì²éºÍ¾ú°ßÖ¸Êý(sihress&L6e plaq¡¤eindex, Pl. D 151. ÑÀö¸ lli Ѫָ Êý ( gingival Irleeding in2dex,CBD161µÄÆÀ¼Û(ɸѡ0ÖÜʱ»ùÏ߯À¹ÀºÍ6ÖÜʱµÄÄ©ÆÚÆÀ¹À)¡£ÔÚ»ùÏßÑÀÖÜÆÀ¼Ûºó¶ÔËùÓÐÊÜÊÔÕß½øÐÐö¸ÉÏÇåÖΡ£ÔÚ»ùÏ߯À¼ÛºÍ×îºóÆÀ¼Ûǰ8 h²»½øÐпÚÇ»Çå½à£¬Ñо¿ÆÚ¼ä²»Ê¹ÓÃÆäËû¿ÚÇ»ÎÀÉú´ëÊ©¡£

1.4¼ì²é±ê×¼Óë·½·¨ËùÓмì²é¾ùÔÚÁÙ´²ÕïÊÒ½øÐУ¬Ê¹Óÿھµ°Ú×ÓºÍÑÀÖÜ̽Õë¶ÔÊÜÊÔÕß½øÐпÚÇ»¼ì²é¡£Ê×ÏȶÔÊÜÊÔÆÎ½øÐÐÑÀ¾ú°ßȾɫ£¬·½·¨Ã¿ÈËš°´Î5µÎȾɫ¼Á£¬Öö¸ÀÊÜÊÔÕߺ¬Êþ15¡¢£¬Ê¹È¾É«¼Á³ä·ÖÓëÑÀÃæ½Ó´¥£¬ÇåË®Êþn£¬È»ºó²ÉÓÃpI.IºÍGBIÆÀ¼Ûö¸ÉϾú°ßºÍÑÀö¸³öѪÇé¿ö¡£Ã¿´ÎÑÀÖܼì²éµÄͬʱҲ¼ì²éÃÅÇ»´½¡¢¼Õ¡¢ÉàµÈÈí×éÖ¯Çé¿ö´¨ÒÔÆÀ¼Û¸ÃÑÀ¸à¶Ô¿ÚÇ»Èí×éÖ¯µÄ¿ÉÄܸ±×÷Óá£

1.5Êý¾Ý´¦ÀíËùÓеÄÊý¾ÝÊäÈë¼ÆËã»ú£¬²ÉÓÃSP5510.ÃÅÈí¼þ½øÐÐͳ¼Æ·ÖÐá£ÓöÀÁ¢Ñù±¾µÄt¼ìÑé·ÖÎöÆÀ¼ÛʹÓÃÑÀ¸à6ÖܺóPLIºÍGBIµÄÇé¿ö¡£

2½á¹û

2.1ÊÜÊÔÕß»ù±¾Çé¿ö95ÃûÑù±¾Íê³ÉÁË×îºóµÄÊÔÑé¡£5¸öÑù±¾ÒòΪÓëÊÔÑéÑÀ¸àµÄÎ޹صÄÔ­Òò£¬Ã»ÓÐ×îÖÕÍê³ÉÊÔÑé¡£ÊÔÑé¹ý³ÌÖÐûÓи±×÷Óõı¨¸æ¡£ÊÜÊÔÕß»ù±¾Çé¿ö¼û±í1.

±í1ÊÜÊÔÕß»ù±¾Çé¿ö








ÊܼìÈËÊý



×é±ð

×Ü

ÄÐ

Å®

ÄêÁä/Ëê

ʵÑé×é

47

23

25

34.8+-8.8

¶ÔÕÕ×é

48

25

23

86.6+-10.1

 

2.2ÊÔÑéǰºóPLI¸Ä±äÇé¿öÊÔÑéǰÊÔÑé×éºÍ¶ÔÕÕ×éPLIÎÞÏÔÖøÐÔ²îÒì(P ¡·0.05)¡£ÊÔÑé6Öܺó£¬

ÊÔÑé×éPLI½µµÍÂÊΪ16_4%£¬ÊÔÑéǰºóPLIÓÐÔÚͳ¼ÆÑ§JÏÔÖøÐÔ²îÒì(p<0.05)¡£¶ÔÕÕ×éÊÔÑéǰºóPLIÎÞÏÔÖø²îÒì(P >0.05)£¬¼û±í2.

±í2.ÊÔÑéǰºóPLI¼Ç·Ö

×é±ð

N

»ùÏß

6ÖÜ

PÖµ

ÊÔÑé×é

47

1.54+-0.34

1.29+-0.40

<0.001

¶ÔÕÕ×é

48

1.60+-0.37

1.57+-0.41


±í3ÊÔÕûǰºóCBIÖ¸Êý¼Ç·Ö

×é±ð

N

»ùÏß

6ÖÜ

PÖµ

ÊÔÑé×é

47

1.14+-0.79

0.47+-0.36

<0.001

¶ÔÕÕ×é

48

1.18+-0.71

1.02+-0.56


2.3ÊÔÑéǰºóCBI¸Ä±äÇé¿öÊÔÑéǰÊÔÑé×éºÍ¶ÔÕÕ×éCBIÎÞÏÔÖøÐÔ²îÒì(P ¡·0.05)¡£ÊÔÑé6Öܺó£¬

ÊÔÑé×éGBI½µµÍÂÊΪ58.8%£¬ÊÔÑé×éǰºóGBIÓÐÔÚͳ¼ÆÑ§Éϸ߶ÈÏÔÖøÐÔ²îÒì(P ¡´0.001)¡£¶ÔÕÕ×éǰºóGBIÎÞÏÔÖø²îÒì(p>0.o5)£¬¼û±í3.

3ÌÖÂÛ

¾ú°ßµÄÐγɺͻýÀÛÔÚÑÀÖܼ²²¡µÄ·¢Éú·¢Õ¹ÖÐÆð·Ç³£ÖØÒªµÄ×÷Ó㬿ØÖƾú°ß¾Í¿ÉÒÔÔ¤·ÀºÍ¿ØÖÆÑÀÖܼ²²¡¡£µ¥´¿»úе¿ØÖƾú°ßÄÜ×è°­ÑÀö¸Ñ×ÒÔ¼°ÑÀÖÜÑ׵ĽøÕ¹µ¨AxFls5oÈÕ±¨µÀ¶ÔÓÚÒÀ´ÓÐÔ²îµÄ»¼¿Í¡¢Æä²¡ÇéÓнøÕ¹»ò¸´·¢µÄÕ÷Ïó£¬Òò´Ë»úеÐÔ¿ØÖƾú°ßÅäºÏÒ©Î↑ʼ½øÈËÈÕ³£Éú»îÒÔÔ¤·ÀÑÀö¸Ñ׵ķ¢Éú£¬ÈçÏ´±ØÌ«ÑÀ¸à¡¢ÈýÂÈÉúÑÀ¸àµÈ£¬ËäÈ»ÕâЩÑÀ¸àÈ¡µÃÁ˽ϺõĿ¹ÑÀö¸Ñ×µÄЧ¹û£¬µ«Í¬Ê±´æÔÚζ¿à»òÕß¿ÉÄܶÔÉíÌåÓк¦µÈ¸±×÷Óá£

±¾Ñо¿µÄÄ¿µÄÊÇÆÀ¹ÀÒ»ÖÖÐÂÐ͵ÄNo\a MinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¶ÔÆÕͨÈËȺµÄÑÀö¸½¡¿µµÄÓ°Ïì¡£ÕâÖÖÐÂÑÀ¸àº¬ÓÐ5%µÄÉúÎï»îÐÔ²£Á§Àë×Ó£¬²»º¬Ë®·ÖÒÔ¼°·ú»¯Îï¡£±¾Ñо¿±íÃ÷ÿÌìʹÓÃÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÁ½´Î£¬6Öܺór.BIϽµ58.8%£¬Í¬Ê±pLIÒ²ÏÔÖøÏ½µ16.4¶ß¡£6ÖܺóÊÔÑé×éÓë¶ÔÕÕ×éµÄPLI(p<0.025)ÒÔ¼°GBI(P¡¶0.001)¾ùÓÐÏÔÖøÐÔ²îÒì¡£

ÉúÎï»îÐÔ²£Á§Àë×ÓÓÃÓÚ¹ÇÔÙÉúÊÖÊõÒÑÓÐ15Äê×î½üµÄÑо¿±íÃ÷ÕâÀà²ÄÁϾßÓÐÄÚÔڵĿ¹¾úÌØÐÔ¡£stoorµÈ½«ÓÐÑÀö¸Ñ×¼°ÑÀÖÜÑ×µÄÓÎÀë×éÖ¯±©Â¶ÓÚÉúÎï»îÐÔ²£Á§Àë×ÓÖÐ10 m inºó£¬°é·ÅÏß·ÅÏ߸˾úÊýÁ¿Ï½µ£¬60 nl inºóÓÎÀë×é֯ʧȥ»îÐÔ£¬Í¬Ê±ÑÀö¸ÆÕßøµ¥°û¾ú£¬ÄÎÊÏ·ÅÏß¾ú¼°±äÐÎÁ´Çò¾ú±©Â¶ÓÚÉúÎï»îÐÔ²£Á§Àë×Ó10.i¡¤ºóҲʧȥËùÓеÄÉúÎï»îÐÔ£¬ÁíÍ⣬AÒ²n¡¾'·¢ÏÖ300²·mµ½500 p-mµÄÉúÎï»îÐÔ²£Á§Àë×Ó¶Ô±äÐÎÁ´Çò¾ú¡¢ÑªÁ´Çò¾ú¡¢ÑÀö¸ÆÕßݵ¥°û¾ú¡¢¾ßºËËó¸Ë¾ú¡¢°é·ÅÏß¹ÊÏ߸˾úÒÔ¼°ÖмäÆÕÀ×ÎÖ¾ú¶¼ÓÐÒÖ¾úЧ¹û¡£×÷ÕßÈÏΪÉúÎï»îÐÔ²£Á§Àë×Óɱ¾úÊÇÒòΪÕâÖÖ»îÐÔ²ÄÁÏÄÜÌá¸ßÈÜÒºÖÐpHÖµ£¬»òÕßÊÍ·ÅÁË´óÁ¿µÄ¸ÆÀë×Ó¡£×î½üµÄÑо¿Ò²Ö¤Êµ¼ÓÈËNora\linÉúÎï»îÐÔ²£Á§Àë×ÓµÄÑÀ¸à£¬Äܽµfص±äÐÎÁ´Çò¾ú¡¢¾ßºËËó¸Ë¾ú£¬ÄÎÊÏ·ÅÏß¾ú¡¢ÑªÁ´Çò¾úÅàÑø»ùÖÐÓÎÀëϸ¾úµÄ»îÐÔ¡£¹Å3%ºÍ10WÉÏÎï»îÐÔ²£Á§Àë×ÓµÄI3Ï¡ÊÍÒºÖÐÄܽµµÍ¾ßÒÀËó¸Ë¾úµÄÉúÎï»îÐÔ4.5¸ö¶ÔÊýÖµÏáѪÁ´Çò¾úÔòɥʧÁËÈ«²¿ÉúÎï»îÐÔ.

ÓëÆäËü¿¹¾úÒ©ÎïµÄÁÙ´²Ñо¿²»Í¬£¬±¾Ñо¿GBI½µµÍ½ÏPLI¼õÉÙ¸üΪÃ÷ÏÔ¡£EberharclµÈ"Ò²±¨µÀÁËÓÃÉúÎï»îÐÔ²£Á§Àë×Ó½¬½øÐÐÊÔÑéÐÔÑÀö¸Ñ×µÄÁÙ´²Ñо¿£¬Ê¹ÓÃÉúÎï»îÐÔ²£Á§Àë×Óºó²¢Ã»Óз¢ÏÖ΢ÉúÎïˮƽµÄ»îÐÔ½µµÍ£¬µ«ÊÇÑ×Ö¢µÄÁÙ´²Ö¸Õ÷¼õµÍ²¢ÇÒILÒ»1bˮƽϽµ

±¾Ñо¿Ö¤ÊµÁ˺¬ÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÔڽ϶Ìֹʱ¼äÄÚÄÜÏÔÖø½µµÍÑÀö¸Ñ×Ö¢£¬²¢ÔÚʹÓÃÆÚ¼äδ¼ûÈκβ»Á¼·´Ó¦¡¢ÊÇÒ»ÖÖ²»º¬Óп¹ÉúËØ»ò·ú»¯ÎïÈ´¶ÔÑÀö¸½¡¿µÓÐÖÎÁÆÐ§¹ûµÄÑÀ¸à¡£µ«ÊÇ£¬ÐèÒª¸ü½øÒ»²½µÄ³¤ÆÚÁÙ´²Ñо¿ÆÀ¼ÛÕâÖÖÉúÎï»îÐÔ²ÄÁ϶ÔÖÎÁÆÑÀö¸Ñ×µÄÔ¶ÆÚÁÆÐ§£¬ÒÔÑо¿Ö¤Êµ(ãè1µÄ½µµÍÊÇ·ñÓÉÓÚ¾ú°ß×é³ÉµÄ¸Ä±äÈçÊýÁ¿µÄ¼õÉÙ»ò¾úÖֵı仯£¬»¹Êǽö½ö¾ú°ß×ÜÊýµÄϽµ¡£

×ÜÖ®£¬±¾Ñо¿ÌáʾNnviM inÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÄÜͨ¹ý¼õÉÙö¸ÉϾú°ß¡¢¼õÇáÑÀö¸³öѪ¶øÏÔÖø¸ÄÉÆÑÀö¸½¡¿µ×´¿ö¡£(¸ÐлÎ人Àû°ÙÉú¿Æ¼¼ÓÐÏÞ¹«Ë¾ÌṩÑÀ¸àºÍÑÀË¢Íê³É±¾ÊÔÑé¡£

²Î¿¼ÎÄÏ×

 

[ 1Stoor P. Kirstila V, Soderling E, et al. Interactions bel wren bio2active glass 553P4 and periodontal pathogens [ J ]. Microb EcolHpalth Dis. 1996, 9 109-1 14

[ 2Allan 1, Xewman H. Wils onM. Antibacterial activity of parlicu2late Bilgtasa against sup ra-and suhgingival bacteria [ J ]. Bio2malprials. 2001. 22 1 683-1 687

 

[ 3 ] Lovelace T B. Mell onig JT, Mpffert RM. et al. Clinical evalua2lion of bioar\ive glass in the trpalmenl of prriodontal osseolls tle2feels in humans [ J ]. J Prriodontol, 1998. 69 1 027-! 035

 

[4]¶ÅÃñȨ£¬ºÏ±£¾ü£¬½­ºº£¬µÈ¡£º¬NovÄ¿mlnÉúÎï»îÐÔ²ÄÁϵÄÑÀ¸à¿¹ÑÀ±¾ÖʹýÃôµÄÁÙ´²ÊÔÑ飬¿ÚǻҽѧÑо¿2004,20(6)641-643

[5]1 Silnps» J. L e H. pprinndotal tlittrn»e in p rrgnanry. II, Corr € la2lion brt wppn oral hygienr and periorlonlal rantlilion IJ 1. ArlaOllonl ol Srand, 1 964. 22 1 2 I-1 35

[ 6 ] Ainamo1. Bay I. Problems and p r upu«als fnr rworcling #ingiviti»and p la¡éiur l J ]. InlprDrnl J. 1975, 25 229-235

[ 7 ] Axelnn on P. Lindhe J. The *ignificanre of maintenance cnrp inthe [rpatmpnl of perindonlal tli»ranp [ J ]. J Clin Pr ri o, 1981, 8281-294

 

[ 8 ] Sinar P, Snrlprling E, Sal onrn Jl. Anrivartprial rfferta of a bi oar2live ¡élasa paelr on oralmicroorgani« mi [ J ]. Aclaotlnnlal Sr and.1998, 56 161-165

[ 9 ] Allan I. Nrwmnn H. Wils on M. Parlirulale Bi oglaas? rrrlucesthe viability of bacterial biofilms fnrmetl on it» »urface in an in-vitro madri [ J ]. Clin Oral ! mp l. 2002, 1 3 53-58[ 10 ] Ebrrhartl j, Rrimrrs N. Dnmmisc : h H. pl al. Thp tffprt of thr

[10]p ical atlministratinn of binartivp glans on inflammatory markrrsnf human pxprrimpnlal gingivilin [ J ]. 8i omalrrial«, 2004, 26

545-1 551

1ÊÕ¸åÈÕÆÚ2005-07-29¡¿(±¾Îı༭ÍôÓ÷ÖÒ)

ÁÙ´²¿ÚǻҽѧÔÓÖ¾

2000 Vol. 16 N. 4 P. 238-239

ÉúÎï»îÐÔ²£Á§Î¢Á£ÖÎÁÆ¿ÚÇ»À£ÑñÁÆÐ§³õ²½¹Û²ì

¡¾ÕªÒª¡¿Ä¿µÄ¹Û²ìÉúÎï»îÐÔ²£Á§Î¢Á£Ó¦ÓÃÓÚ¸´·¢ÐÔ¿ÚÇ»À£ÑñÖÎÁƵÄÁÆÐ§¡£·½·¨120

Ãû¸´·¢ÐÔ¿ÚÇ»À£Ññ»¼ÕßËæ»ú·ÖΪÁ½×飬¶ÔÕÕ×鲡ÈËÐд«Í³ÖÎÁÆ£¬¶øÊµÑé×鲡ÈËÔÚÀ£Ññ¾Ö²¿Ó¦

ÓÃÉúÎï»îÐÔ²£Á§Î¢Á£Ã¿ÈÕÈý´Î£¬²¢¼Ç¼×ÔÓÃÒ©ÖÁÀ£ÑñÓúºÏµÄʱ¼ä¡£½á¹ûÉúÎï»îÐÔ²£Á§Î¢Á£

¿ÉÃ÷ÏÔ¼õÇá¿ÚÇ»À£ÑñµÄÌÛÍ´²¢¿ÉʹÀ£ÑñÓúºÏ¼Ó¿ì¡£½áÂÛ³õ²½¹Û²ì±íÃ÷ÉúÎï»îÐÔ²£Á§Î¢Á£¶Ô

¿ÚÇ»À£ÑñµÄÖÎÁÆÓÐÓ¦ÓüÛÖµ¡£

¡¾¹Ø¼ü´Ê¡¿ÉúÎï»îÐÔ²£Á§ÖÎÁƸ´·¢ÐÔ¿ÚÇ»À£Ññ

¡¾ÖÐͼ·ÖÀàºÅ¡¿R781.5¡¾ÎÄÏ×±êʶÂë¡¿A¡¾ÎÄÕ±àºÅ¡¿1003-1634(2000)

04-0238-02

The primary clinical observation of the bioglass particulate used in the treatment of RAU

 

Zhang xueguang
(Yantai municipal Laiyang central hospital, Yantai, 265200)
"H.

[Abstract] objective To observe the clinical effect of B¨©oglass used in the
treatment of RAU. Methods 120 patients with RAU were divided ĵnto two groups, the
Patients in the control group were given traditional local treatment and the patients
in experimental group were given Bioglass particulate in the ulcer area 3 times per
day and record the time that the ulcer heal. Results Bioglass can reduce the pain
oF ulcer greatly and make the ulcer heal more rapid than traditional drugs do it.
Conclusion The primary observation suggests that Bioglass could be used in the local
treatment of RAU.
[Key 1rords] Bioglass particulate ; Trea tment ; RAu
²ÄÁÏÓë·½·¨
1£¬²¡ÀýÑ¡Ôñ
Ëæ»úÑ¡Ôñ1998Äê¡«ı999ÄêÔÚÎÒÔº¿ÚÇ»¿ÆÃÅÕï¾ÍÕïµÄ¸´·¢ÐÔ¿ÚÇ»À£Ññ»¼Õß¹²12oÈË£¬·Ö
ΪʵÑé×é¼°¶ÔÕÕ×éÁ½×飬ÿ×é¸÷60ÈËÆäÖÐʵÑé×éÄÐ27ÈË£¬Å®33È˶ÔÕÕ×éÄÐ25ÈË£¬Å®
35ÈË£¬»¼ÕßÄêÁäΪ21¡«63Ë꣬²¡Ê·×Ô1ÄêÖÁ10Äê²»µÈ£¬ÆäÖÐÿ×é¾ù°üÀ¨ÇáÐͿڴ¯¼°ÏÙÖÜ¿Ú
´¯»¼Õß¡£

2.²ÄÁÏ

ÉúÎï»îÐÔ²£Á§Î¢Á£Ñ¡ÓÃÃÀ¹úÉúÎï²ÄÁϹ«Ë¾Éú²úµÄDermglass¡£·Û×´ÖÆ¼Á£¬ÆäÖ÷Òª³É·ÝΪ
«a0. SIO. P, O. Na, O.

3·½·¨
¶ÔÕÕ×é²ÉÓ󣹿ÖÎÁÆ·½·¨£¬À£Ññ¾Ö²¿Ê¹ÓÃÇà´ïÓÍ(Ö÷Òª³É·ÝΪÇà÷ì¼°´ï¿ËÂÞÄþ)ֹʹ£¬
Ö¢×´½ÏÖØÕ߿ڷþÉöÉÏÏÙÆ¤Öʼ¤ËØ£¬ÉϱÛÄÚ²àÆ¤ÏÂ×¢Éä×ªÒÆÒò×Ó£»ÊµÑé×é³ýÀ£Ññ¾Ö²¿Ó¦ÓÃÉúÎï
»îÐÔ²£Á§Î¢Á£Í⣬ÆäÓàÖÎÁÆÍ¬¶ÔÕÕ×飬ʹÓÃʱ½«ÉúÎï»îÐÔ²£Á§Î¢Á£¸²¸ÇÓÚÀ£Ññ±íÃæ£¬Ã¿ÈÕÈý
´Î£¬¼Ç¼×Ô¾ÍÕïºó¿ªÊ¼ÓÃÒ©ÖÁÀ£ÑñÓúºÏµÄʱ¼ä¼°ÓÃÒ©ºóÌÛÍ´ÏûʧÇé¿ö¡£

½á¹û

¡¿.ËùÓв¡ÈË(°üÀ¨¶ÔÕÕ×鼰ʵÑé×é)£¬×ÔÓÃÒ©ÖÁÓúºÏ֮ʱ¼ä(±í1)¡£
2£¬ÊµÑé×鲡ÈËÓ¦ÓÃÉúÎï»îÐÔ²£Á§Î¢Á£ºó£¬´ó¶àÊý²¡È˸ÐÀ£Ññ´¦ÌÛÍ´Ã÷ÏÔ¼õÇᣬʹÓúó
ÎÞÃ÷ÏÔ¾Ö²¿´Ì¼¤¸Ð£¬ÊµÑé×éÌÛÍ´»º½âÂÊÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×é(±í2)¡£


±í1ʵÑéÌï¼°¶ÔÕÕ×éÀ£ÑñÓúºÏʱ¼ä(Ìì)

×é±ð

ÀýÊý

ƽ¾ùÓúºÏʱ¼ä¼°±ê×¼²î

¾ÍÕïǰ»¼²¡Ê±¼ä¼°±ê×¼²î

ÊÔÑé×é

60

4.83---0.537

2.78---0.255

¶ÔÕÕ×é

60

6.79---0.0608

2.87---0.309



¾­u¼ìÑ飬P¤¯0.01£¬Óзdz£ÏÔÖø²îÒì¡£
±í2ʵÑé×é¼°¶ÔÕÕ×éÌÛÍ´»º½âÇé¿ö

×é±ð

ÀýÊý

»º½âÌÛÍ´ÈËÊý

»º½âÂÊ

ÊÔÑé×é

60

47

78.33%

¶ÔÕÕ×é

60

28

46.67%

¾­¿¨·½¼ìÑ飬p<0.01,Á½×éЧ¹ûÓзdz£ÏÔÖø²îÒì

ÌÖÂÛ
1.´«Í³¿ÚÇ»À£ÑñµÄ¾Ö²¿ÓÃÒ©Ò»°ã¾ùΪ¾Ö²¿Âé×í¼Á¼°ÊÕÁ²¼Á»ò¿¹ÉúËØµÄ»ìºÏÖÆ¼Á£¬Æð¾Ö²¿Ö¹Í´ÏûÑ××÷Ó㬵«²»ÄÜËõ¶Ì²¡³Ì£¬½ö¿É¼õÇá¾Ö²¿ÌÛÍ´Ö¢×´¶øÉúÎï»îÐÔ²£Á§Î¢Á£µÄÓ¦ÓÿÉËõ¶Ì²¡³Ì£¬´Ù½øÀ£ÑñµÄÓúºÏ£¬ÇÒɽj¡ãÆäÓëÈí×éÖ¯½áºÏ½ôÃÜ£¬´Ó¶ø±ÜÃâÁËÍâ½ç¶ÔÀ£ÑñÃæµÄ´Ì¼¤£¬¼õÇáÁËÌÛÍ´¡£
2.ÉúÎï»îÐÔ²£Á§(Bioglass)ÊÇÒ»ÖÖÐÂÐ͵ÄÈËÒ»¡¾²Ä–`£¬¾ßÓÐÁ¼ºÃµÄÉúÎïÏàÈÝÐÔºÍÉúÎï»îÐÔ£¬´«Í³ÉÏÓÃΪÈË¡¿£º¹Ç»ò¹ÇiÐãµ¼¼Á£¬µ«ÊǽÏеÄÑо¿·¢ÏÖÆä²»µ«ÄÜÓëØ¥×éÖ¯½á£¬¶øÇÒÄÜÓëÈí×éÖ¯½áºÏ´Ù½øÈí×éÖ¯µÄttj/t£¬ÆäÁ£¶È¡¶90 0 m£¬É½ÓÚÆä¾ßÓжÀÌØµÄ±íÃæ»îÐÔ£¬µ±ÓëÈí×éÖ¯½Ó´¥Ê±£¬´å´å˲¼äÓë×éÖ¯1˾·¢ÉúÀëϽ»»»£¬Ìá¸ß¾Ö²¿¿¹Ñ¹ºÍ½Ðfl'L.²¢ÔÚÆä±íÃæÐγɽÏÇ¿µÄ¸ºµçÊÆ¶øÎü¸½ÖÜΧµÄϸ°û¡¢ÏËάµ°°×¼°½ºÔ­µ°°×£¬²¢Í¨¹ý¸Æ¡¢ÁײãµÄ¿ìËÙÐγɣ¬ÔÚÀ£ÑñÄÚÎȶ¨ÕâЩϸ°ûºÍµ°°×£¬Í¬Ê±´Ùʹϸ°û·ÖÃÚ½ºÔ­µ°°×£¬´Ó¶ø¼ÓËÙÀ£ÑñµÄÓúºÏ¡£
3£¬ÉúÎï»îÐÔ²£Á§Î¢Á£¼º³õ²½ÏÔʾ³ö¶Ô¿ÚÇ»À£Ññ¶ÀÌØµÄÁÆÐ§£¬ÖµµÃ½øÐнøÒ»²½µÄÑо¿¼°ÁÆÐ§¹Û²ì¡£

×÷Õßµ¥Î»ÕÅѧ)-(265200ÑĮ̀£¬ÑĮ̀ÊÐÀ³ÑôÖÐÐÄÒ½Ôº)

²Î¿¼ÎÄÏ×
¡¾1¡¿ÔÀËÉÁäÖ÷±à£¬¿ÚÇ»ÄÚ¿ÆÑ§¡¾M¡¿£¬µÚ¶þ°æ£¬±±¾©ÈËÃñÎÀÉú³ö°æÉ磬1987 357¡«362.
[2] Hench L, Wilson J. Surface-active biomaterials U]. Science, 1984 : 226 : 630-636.
[3] Wilson J, Hall M, Hench L.. Tissue response to Bioglass endosseous ridge
maintenance implants [J] 1 0ral Implantol, 1993 ; 19 : 295-302.

 


ÁªÏµÈÈÏߣº400-700-2499
¹«Ë¾ÓÊÏ䣺oholv@163.com
¹«Ë¾µØÖ·£º¹ã¶«Ê¡¹ãÖÝÊз¬Ø®Çø¶«»·½Ö·¬Ø®´óµÀ±±818ºÅA3¶°¶þÂ¥

ÏßÉÏÉ̳Ç

¿ÚÇ»½¡¿µ

¹ØÓÚÎÒÃÇ

ÓÑÇéÁ´½Ó£º

ɨÂë¹Ø×¢¹«ÖÚºÅ

seo seo